One of the two recently approved Alzheimer's drugs has been submitted for coverage under the National Health Insurance (NHI) programme and could be considered for inclusion by the end of the year, National Health Insurance Administration (NHIA) Director-General Shih Chung-liang announced
The Far Eastern Memorial Hospital in New Taipei City announced that Kisunla—the brand name for donanemab, a monoclonal antibody developed by US pharmaceutical company Eli Lilly and Co—will be administered for the first time in Taiwan today.
There are currently two FDA-approved drugs for Alzheimer’s treatment in Taiwan, with one having already applied for NHI coverage.
The other drug, Leqembi, is the brand name for lecanemab, a monoclonal antibody developed through a collaboration between Japanese pharmaceutical company Eisai and US-based Biogen.
Both Kisunla and Leqembi have shown effectiveness in slowing cognitive decline in patients with early-stage Alzheimer’s disease, Ms Shih said.